Peter J. Goebell

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

Vinata B. Lokeshwar, Tomonori Habuchi, H. Barton Grossman et al. · Urology · 2005 · 431 citations

Medicine, Oncology, Urology +16

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

John C. Araujo, Géralyn C. Trudel, Fred Saad et al. · The Lancet Oncology · 2013 · 231 citations

Medicine, Oncology, Urology +14

Efficacy and Safety of TachoSil ® as Haemostatic Treatment versus Standard Suturing in Kidney Tumour Resection: A Randomised Prospective Study

Stefan Siemer, Sven Lahme, Stefan Altziebler et al. · European Urology · 2007 · 152 citations

Medicine, Oncology, Surgery +12

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer

Christian Eichelberg, Walter L. Vervenne, Maria De Santis et al. · European Urology · 2015 · 142 citations · Full text

Medicine, Oncology, Pharmacology +16